The obtained data indicated that an elevated expression level of TMPRSS2 was linked with significant OS prognosis in patient with bladder, head–neck squamous cell, kidney renal papillary cell, liver hepatocellular, lung adeno, stomach adeno and uterine corpus endometrial carcinoma as well as thymoma, whereas the association of higher expression with bad DFS prognosis in patient with breast cancer, ovarian cancer, rectum adenocarcinoma and sarcoma (Figures 6 and 7 and Table 2). Here, TMPRSS2 is linked to ovarian cancer.